Skip navigation
Skip navigation

NLRP3 inflammasome blockade reduces liver inflammation and fibrosis in experimental NASH in mice

Mridha, Auvro; Wree, Alexander; Robertson, Avril; Yeh, Matthew; Johnson, Casey D.; Van Rooyen, Derrick; Haczeyni, Fahrettin; Teoh, Narcissus; Savard, Christopher; Ioannou, George; Masters, Seth; Schroder, Kate; Cooper, Matthew A.; Feldstein, Ariel E.; Farrell, Geoffrey


Background & Aims: NOD-like receptor protein 3 (NLRP3) inflammasome activation occurs in Non-alcoholic fatty liver disease (NAFLD). We used the first small molecule NLRP3 inhibitor, MCC950, to test whether inflammasome blockade alters inflammatory recruitment and liver fibrosis in two murine models of steatohepatitis. Methods: We fed foz/foz and wild-type mice an atherogenic diet for 16 weeks, gavaged MCC950 or vehicle until 24 weeks, then determined NAFLD phenotype. In mice fed an...[Show more]

CollectionsANU Research Publications
Date published: 2017-05
Type: Journal article
Source: Journal of Hepatology
DOI: 10.1016/j.jhep.2017.01.022
Access Rights: Open Access


File Description SizeFormat Image
83986158.pdfAuthor Accepted Manuscript2.28 MBAdobe PDFThumbnail

This item is licensed under a Creative Commons License Creative Commons

Updated:  17 November 2022/ Responsible Officer:  University Librarian/ Page Contact:  Library Systems & Web Coordinator